Radiation Therapy With or Without Antiandrogen Therapy in Treating Patients With Stage I or Stage II Prostate Cancer
A PHASE III TRIAL OF THE STUDY OF ENDOCRINE THERAPY USED AS A CYTOREDUCTIVE AND CYTOSTATIC AGENT PRIOR TO RADIATION THERAPY IN GOOD PROGNOSIS LOCALLY CONFINED ADENOCARCINOMA OF THE PROSTATE
Sponsor: National Cancer Institute (NCI)
Listed as NCT00002597, this PHASE3 trial focuses on Prostate Cancer and remains completed. Sponsored by National Cancer Institute (NCI), it has been updated 9 times since 1994, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jul 2018 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 4 earlier versions
-
Jun 2018 — Jul 2018 [monthly]
Completed PHASE3
-
Jul 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Feb 2017 — Jul 2017 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Oct 1994
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Cancer Institute (NCI)
- Radiation Therapy Oncology Group
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Akron, United States, Albany, United States, Albuquerque, United States, Allentown, United States, Amarillo, United States, Anchorage, United States, Anderson, United States, Ann Arbor, United States, Annapolis, United States, Arlington Heights, United States and 176 more location s